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1. Introduction
Embolic problems are a well‐established cause of substantial morbidity and mortality. The 
challenging aspect of management is recognition of the multi‐factorial events that ultimately 
result in an embolic problem. First and foremost in management is often the acute events 
that bring the patient to medical attention. While such events, in themselves, can be dramatic 
in their morbidity and/or mortality—and, therefore, require immediate attention—emphasis 
must also focus on the precipitating factors that precipitate the embolism. When possible, 
and reasonable, it is important to identify the source of the embolism, the destination (or des‐
tinations) of the embolic material, and the characteristics that might have contributed to the 
development of the primary source. Management is often structured around controlling the 
embolism and its clinical consequences.
2. Principles of care
One of the most common thrombo‐embolic complications is stroke. Cerebrovascular conse‐
quences can span the spectrum of clinical presentations from events that can be minor, self‐
limited, and potentially asymptomatic events to those that are catastrophically debilitating or 
fatal. Common causes include thrombotic material from a cardiac source—typically clots from 
the left atrial appendage in patients with atrial fibrillation [1]. Other cardiac sources include 
left ventricular thrombus in patients with significant wall motion abnormalities or apical 
aneurysms/dysfunction in the setting of previous myocardial infarctions or a depressed ejec‐
tion fraction, infectious sources from endocarditis (also typically intra‐cardiac), paradoxical 
emboli from intra‐cardiac shunts (such as a patent foramen ovale), and less common cardiac 
causes—including benign and malignant tumors [2]. While much energy is focused on cardiac 
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source and systemic effects, it is critical to recognize that there are many others—and often 
less common or unusual causes. In addition, the foundations for embolic therapy include [3]:
(1) Anticoagulation or anti‐platelet therapies to potentially minimize the impact of the initial 
event.
(2) Interventions—either pharmacologic or mechanical to try to dissolve or remove the distal 
embolism.
(3) Control or management of the primary source to reduce the risks for recurrence.
(4) Long‐term therapies to control the circumstances that resulted in the initial primary 
sources.
Even though neurologic complications tend to be the most fear, it is important to realize that 
systemic complications to visceral organ (i.e., hepatic, renal, intestinal) and the extremities 
can be just as morbid or potential fatal [4, 5]. The focus of many chapters in this text is an 
update and review of some of these unusual embolic sources. While it is important to recog‐
nize that many common clinical problems and their treatments, can lend themselves to the 
development of protocols and guidelines, some of the more uncommon or unusual presenta‐
tions and problems can present as considerable diagnostic and therapeutic challenges. The 
purpose of many of the chapters in this text is to review the data and collective experiences of 
some of the different types of embolic diseases and to serve as a guide to therapy.
3. Project focus
In addition, even though there are extensive reviews of some of the more common embolic 
problems—such as left atrial appendage clots, stroke in the setting of either cardiac or non‐
cardiac sources, and the diagnosis and medical management of the full spectrum of acute and 
chronic pulmonary thromboembolic disease, these important clinical topics are not considered, 
other than rarely discussed surgical management, in the contents of this book. The reasons for 
their exclusion are simple—each topic can clearly be a book in outright (and there are already 
entire texts devoted to each topic) and even a basic review would overwhelm the primary 
purpose of this project. Furthermore, the fields in these areas are changing so quickly in terms 
of diagnostic tools, medical therapies, interventional options, and the standards of care and 
professional society guidelines that inclusion of some of those topics would only quickly result 
in an out‐of‐date reference [6]. Nevertheless, there are some principles that are evolving in the 
management of embolic disease that are comment regardless of the etiologies. The common 
principles are echoed as themes throughout this text, but warrant specific discussion.
4. Team‐base care
As with many other contemporary disease management guidelines—such as cancers and struc‐
tural heart disease—the focus is on a multi‐disciplinary team approach to the diagnosis and 
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management [7, 8]. The purposes and goals of a team approach should be inherently obviously, 
but developing and maintaining them often requires substantial leadership in bringing together 
various disciplines with a patient‐centered focus. Professional and disease centric “silos” and 
traditional models of patient care, including sometimes one‐way, fragmented, and ill‐coordi‐
nated referrals have evolved in the team‐based care. Often such teams will have a coordina‐
tor—aptly called a “navigator”—whose primary purpose is to help navigate and coordinate 
the care of the individual patients [9]. As with all journeys, the Navigator will ensure a safe and 
effective travel, through what is often a complex and challenging path from initial diagnosis to 
cure. While a Navigator might not be the first healthcare provider a patient encountered when 
entering into a disease management process, they ultimately serve as the focal point person for 
care. Even as a patients is individually evaluated by members of the Team, internal referral to 
the Navigator can help organize the clinical data and help track and coordinate a management 
plan. Navigators can arrange for testing and follow‐up appointments to help not only insure 
a timely and efficient work‐up, but also insure that team‐defined care plans are maintained. 
Typically, a Navigator will help compile all of the relevant diagnostic testing, including critical 
components of the history and physical exams and provide a framework such that each patient’s 
unique presentation is discussed in a timely manner by all of the disciplines represented by the 
team. Disciplines represented on such teams can vary, but are often comprised of the core spe‐
cialties that traditionally manage either the organ systems or the diseases in question. However, 
there are some key disciplines that often serve as critical team members:
1. Medical specialists (i.e., cardiologists, pulmonologist, oncologists).
2. Surgical specialists (i.e., oncologic surgeons, cardiothoracic surgeons, general surgeons).
3. Therapy‐specific specialists (e.g., interventional cardiology/radiology, radiation/medical 
oncology).
4. Palliative care and hospice medicine.
5. Primary care, hospitalists, or geriatric specialists.
6. Imaging specialists.
7. Advanced practice healthcare providers (e.g., nursing, respiratory therapy, pharmacy, 
perfusionists, imaging technicians)
In addition, such teams need to be open to all healthcare providers who would be interested 
in attending and participating. Additional specialists, in specific cases, should be asked to par‐
ticipate to lend their expertise and insights when patients present with a more advanced set 
of circumstances—such as a nephrologist might be asked to participating in the discussion of 
a patient who also immunosuppressed from a kidney transplant, or a neurologist and infec‐
tious disease experts might be called upon to discuss a patient with a stroke from infectious 
endocarditis. The overriding principle behind such team‐based care is that each case is pre‐
sented with a focus on evidence based medicine guidelines, local or regional experiences or 
expertise, objective review of all of the key tests, and a unified consensus as to “best” approach 
to the management of the patient and their problems. The management of a patient with 
embolic diseases should also follow such a framework. While the acuteness of a  presentation 
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and need for immediate or emergent therapy might preclude a “weekly team conference,” 
it should not change from the borrowing of an established institutional structured approach 
to the problem. A physical or virtual meeting and discussion of the core disciplines can occur 
at any time, and hopefully with an existing algorithm in place for disease triage and manage, 
such meetings can be arranged and effective care‐plans determined at any time—even in the 
absence of a formal “on‐call” schedule provided the members are committed to the principles 
of such team‐based care. The current models that are used for Structural Heart Disease or 
Acute Pulmonary Embolism Teams, throughout of the scope of this text, are being written 
about more extensively in the literature and might help provide a structure [10, 11].
Important concepts that represent themes throughout this text are that include:
1. Not all sources of embolic disease reflect in here patient co‐morbidities—such as atrial fibril‐
lation, atherosclerotic vascular disease, endocarditis, or deep vein thrombosis—just to name 
a few common intrinsic causes. Some sources may be initially extrinsic to the patient or 
iatrogenic, such as retained foreign bodies (e.g., guide wires lost during central line place‐
ment) or objects that erode into the vascular system after trauma (i.e., bullet fragments).
2. However, it is important to also realize—as emphasized in several chapters—that the 
pathophysiologic consequences of several chronic disease states, such as liver and renal 
disease, might predispose patients to increased risks for complex embolic problems. An 
understanding of the complex biology is a cornerstone to effective management.
3. Similarly, when evaluating a patient with an embolic problem, it is important to consider 
that not all embolisms are “organic” in nature. While most embolic material consists of bio‐
logic material such as clot, atherosclerotic debris, infectious material (i.e., vegetations)—or 
typically, a combination of one or more components, it is important to consider (as men‐
tioned above) that some embolic material might not be organic, or biologic.
4. Another important concept that is addressed in some of the chapters in this text is that 
management might vary based upon not only the patient’s clinical status, but also the na‐
ture of the embolic material. While anti‐coagulation or anti‐platelet agents still represent a 
cornerstone to treatment of most embolic complications with the underlying principle that 
such therapies might minimize the consequences of vascular occlusion with propagation 
or worsening thrombotic material, acute or definitive treatment might require more inva‐
sive therapies. Several of the chapters in this text outline the role and specific techniques 
for surgical management of embolic complication. With so much emphasis on therapies 
that focus on manipulations of the clotting cascade—such as anticoagulation, fibrinolysis, 
or anti‐platelets agents—as with all multi‐disciplinary approach to complex problems, surgical 
management options must be considered.
5. Conclusions
It is important to recognize that when faced with a patient with an embolic complication, 
management can be complexed. Clearly, early and aggressive diagnostic and therapeutic 
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 initiatives are critical to prevent further complications. As with many problems, a multi‐dis‐
ciplinary team approach to care is an evolving foundation that is important for optimizing 
outcomes. Unusual embolic complications, thought far less common than atherosclerotic 
or those of an intrinsic cardiac source, must be considered and managed using a similar 
paradigm of care. It is the fundamental purpose of this text to hopefully outline some of the 
more unusual causes of embolic diseases and emphasize the experiences and data that can 
guide therapy.
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